Momenta Pharmaceuticals, Inc. (MNTA)

[vinmantoo]

pollywog,

Right on target with your analysis. The big difference regarding mCopaxone vs mLovenox is that MNTA's share of revenues from their partner won't change if a second generic enters the market. A second generic is what kept MNTA's price lower. If MNTA had the Copaxone type deal for mENOX, they would be getting $80-$100 million/quarter despite Amphastar's entry. That would have made a dramatic difference in MNTAs stock price.